59
1
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40121 |
SHP2-D26
SHP2-D26 |
PROTACs | PROTAC |
SHP2-D26 is a highly potent and effective SHP2 degrader. Its mechanism of action involves the induction of SHP2 degradation through binding to VHL-1 and SHP2 proteins. Additionally, the degradation of SHP2 induced by SHP2-D26 is dependent on neddylation and proteasome activity. | |||
T39640 |
JAB-3068
SHP2-IN-6 |
Phosphatase | Metabolism |
JAB-3068 (SHP2-IN-6) 是一种高效的 SHP2 抑制剂, 具有抗癌抗肿瘤活性,可用于研究乳腺癌肺癌和食道癌。 | |||
T40250 |
SHP2 protein degrader-1
SHP2 protein degrader-1 |
Others | Others |
SHP2 protein degrader-1 is a highly efficient allosteric inhibitor targeting SHP2. It effectively induces degradation of SHP2 protein, resulting in cell apoptosis. This compound shows promising potential for studying diseases associated with SHP2. | |||
T39658 |
RMC-4630
SHP2-IN-7,RMC-4630 |
Phosphatase | Metabolism |
RMC-4630 (SHP2-IN-7) 是 SHP2 的抑制剂。 | |||
T39641 |
SHP2-IN-6 hydrochloride
SHP2-IN-6 hydrochloride |
Others | Others |
SHP2-IN-6 hydrochloride is a highly potent inhibitor of SHP2 with an IC50 of 25.8 nM. | |||
T12903 |
SHP2 IN-1
|
Others | Others |
SHP2 IN-1 is an allergic SHP2 (PTPN11) inhibitor(IC50 : 3 nM). | |||
T63993 |
SHP2 inhibitor LY6
|
Others | Others |
SHP2 inhibitor LY6 (LY6) 是一种有效的、选择性的 SHP2 抑制剂 (IC50: 9.8 μM)。SHP2 inhibitor LY6 能够阻碍 SHP2 介导的细胞信号传导和增殖。 | |||
T81162 |
SHP2-IN-20
|
Others | Others |
SHP2-IN-20 (compound 193)为SHP2抑制剂,具有3 nM的IC50值,适用于胶质母细胞瘤研究。 | |||
T79108 |
SHP2-IN-14
|
Others | Others |
SHP2-IN-14 (compound 27) 为一种口服生效SHP2变构抑制剂(IC50=7 nM),展示抗肿瘤作用。该化合物能够有效抑止小鼠NCI-H358肿瘤模型生长,且具备优良药代动力学属性和安全性。 | |||
T74430 |
SHP2 protein degrader-2
|
PROTACs | PROTAC |
SHP2protein degrader-2 (SHP2-D26) 是一种SHP2蛋白PROTAC 降解剂。SHP2protein degrader-2 可降低各种癌细胞中SHP2的表达水平。 | |||
T61891 |
SHP2-IN-8
|
Others | Others |
SHP2-IN-8 是一种可逆、非竞争性、选择性、高效性的变构SHP2抑制剂(IC50= 23 nM,Ki= 22 nM),在细胞中也有效果。SHP2-IN-8 能引起显著的热位移(ΔTm = 7.01 ℃)。SHP2-IN-8 可抑制AKT 的磷酸化,诱导 Hela 细胞凋亡 (apoptosis)。 | |||
T79412 |
SHP2-IN-16
|
Others | Others |
SHP2-IN-16(化合物222)作为SHP2抑制剂,具有1 nM的IC50值,适用于胶质母细胞瘤研究。 | |||
T78896 |
SHP2-IN-22
|
Others | Others |
SHP2-IN-22 作为变构抑制剂,靶向SHP2,具有 17.7 nM 的 IC50。该化合物能够有效抑制MIA PaCa-2胰腺癌细胞的增殖、迁移和侵袭行为。SHP2-IN-22 主要用于研究含Kirsten大鼠肉瘤病毒癌基因(KRAS)突变型的癌症。 | |||
T78611 |
SHP2-IN-5
|
Others | Others |
SHP2-IN-5(化合物1)为SHP2抑制剂,IC50为97 nM。SHP2,一种非受体型蛋白酪氨酸磷酸酶,与细胞生长及增殖紧密相关。SHP2-IN-5可能对抑制癌症和其他与SHP2有关的疾病具有治疗潜力。 | |||
T81161 |
SHP2-IN-21
|
Others | Others |
SHP2-IN-21(化合物208)是一种SHP2抑制剂,其IC50为3 nM,适用于胶质母细胞瘤研究。 | |||
T78694 |
SHP2-IN-13
|
Others | Others |
SHP2-IN-13是一种针对SHP2“tunnel site” 的变构抑制剂,具备高选择性及口服活性,IC50值为83.0 nM。该化合物可作为研究潜力药物,用于治疗携带RTK致癌驱动因素的癌症以及SHP2相关疾病。 | |||
T81163 |
SHP2-IN-19
|
Others | Others |
SHP2-IN-19(compound 183),作为SHP2抑制剂,展现出3 nM的IC50值,主要应用于胶质母细胞瘤研究。 | |||
T81165 |
SHP2-IN-17
|
Others | Others |
SHP2-IN-17(化合物192)作为SHP2抑制剂,具有2 nM的IC50值,适用于胶质母细胞瘤研究。 | |||
T72839 |
SHP2/HDAC-IN-1
|
Others | Others |
SHP2/HDAC-IN-1 是一种变构的 SHP2/HDAC 双重抑制剂,IC50值分别为 20.4 nM (SHP2) 和 25.3 nM ( HDAC1)。SHP2/HDAC-IN-1 通过激活 T 细胞、增强抗原呈递功能和促进细胞因子分泌来触发抗肿瘤免疫反应。SHP2/HDAC-IN-1 可用于癌症的免疫治疗研究。 | |||
T72836 |
SHP2/CDK4-IN-1
|
Others | Others |
SHP2/CDK4-IN-1(化合物10)是一种针对SHP2和CDK4的口服双重抑制剂,具有IC50值分别为4.3和18.2 nM。该化合物能有效引起G0/G1期阻滞,抑制TNBC细胞的增殖,并在EMT6同源小鼠模型中展现出明显的抗肿瘤活性,适用于三阴性乳腺癌(TNBC)的研究。 | |||
T61701 |
SHP2-IN-9
|
Others | Others |
SHP2-IN-9 is a potent inhibitor (IC50 = 1.174 μM) specifically targeting the SHP2 protein, displaying improved penetration across the blood-brain barrier. It exhibits a remarkable 85-fold selectivity for SHP2 over SHP1. By inhibiting SHP2-mediated cell signal transduction and impairing cancer cell proliferation, SHP2-IN-9 effectively suppresses the growth of both cervix cancer tumors and glioblastoma in vivo [1]. | |||
T81164 |
SHP2-IN-18
|
Others | Others |
SHP2-IN-18(化合物183)作为SHP2抑制剂,具有3 nM的IC50。该化合物适用于胶质母细胞瘤研究。 | |||
T4340 |
SPI-112
|
Phosphatase | Metabolism |
SPI 112 是一种选择性的、有效的、竞争性的SHP2 (PTPN11)抑制剂,对SHP2,蛋白酪氨酸磷酸酶 (PTP) 和 PTP1B 的IC50分别为 1 μM,18.3 μM 和 14.5 μM。 | |||
T13176 |
TNO155
Batoprotafib |
Phosphatase | Metabolism |
TNO155 是具有口服活性野生型SHP2的选择性变构抑制剂 (IC50= 0.011 µM)。它有研究 RTK 依赖性恶性肿瘤(尤其是晚期实体瘤)的潜力。 | |||
T9196 |
IACS-13909
BBP-398 |
Phosphatase | Metabolism |
IACS-13909 (BBP-398) 是具有口服活性的、选择性的 SHP2变构抑制剂,其 IC50=15.7 nM,Kd=32 nM。与其他磷酸酶相比,它对 SHP2的选择性更高。它能够抑制受体酪氨酸激酶 (RTK)/MAPK 途径的信号传导,并具有抗癌作用。 | |||
T28410 |
PHPS1
PHPS-1,PHPS 1 |
Phosphatase | Metabolism |
PHPS1 是 Shp2的选择性抑制剂,对 Shp2,Shp2-R362K,Shp1,PTP1B 和 PTP1B-Q 的 Ki 分别为 0.73,5.8,10.7,5.8 和 0.47 μM。 | |||
T22276 |
Bis(maltolato)oxovanadium(IV)
双(麦芽醇)氧钒(IV),BMOV,Bis maltolato oxovanadium,Bis(maltolato)oxovanadium (IV),bis maltolato oxo vanadium,Bis(maltolato)oxovanadium (IV) |
Phosphatase; Others | Metabolism; Others |
Bis(maltolato)oxovanadium(IV) (BMOV) 是一种有效的胰岛素增敏剂,也是一种有效的、竞争性的、可逆的、口服具有活性的光谱蛋白酪氨酸磷酸酶 (PTP) 抑制剂。它抑制HCPTPA,PTP1B,HPTPβ和SHP2的IC50分别为 126 nM,109 nM,26 nM 和 201 nM。 | |||
T68409 |
SHP244
|
Others | Others |
SHP244 is an allosteric inhibitor of SHP2 with modest thermal stabilization of the enzyme. | |||
T3544 |
SHP099 hydrochloride
|
Phosphatase; Others | Metabolism; Others |
SHP099 hydrochloride 是一种有效的、选择性的、口服生物可利用的、有效的 SHP2 抑制剂。 | |||
T16350 |
NSC-87877
|
Apoptosis; Phosphatase | Apoptosis; Metabolism |
NSC-87877 是一种Shp2和Shp1蛋白质酪氨酸磷酸酶抑制剂,IC50值分别为0.318 μM 和0.355 μM。它还抑制双特异性磷酸酶26。 | |||
T16762 |
RMC-4550
|
Phosphatase | Metabolism |
RMC-4550 是选择性的蛋白酪氨酸磷酸酶 2 的变构抑制剂,其IC50=0.583 nM。 | |||
T3564 |
SHP099
SHP099 free base,SHP 099,SHP-099 |
Phosphatase; PERK | Apoptosis; Metabolism |
SHP099 (SHP099 free base) free base 是一种选择性的,有效的,有口服活性的 SHP2抑制剂,IC50=70 nM。 | |||
T73552 |
BPDA2
|
Phosphatase | Metabolism |
BPDA2 是一种具有选择性和高效性的 SHP2 抑制剂,对 SHP2、SHP1、SHP1B 的 IC50 值分别为 92.0 nM、33.39 μM、40.71 μM。DBDA2 具有抗癌抗肿瘤活性,以浓度依赖性方式抑制乳腺癌细胞的锚定非依赖性生长和癌症干细胞特性。BPDA2 可用于研究乳腺癌。 | |||
T4627 |
SPI--112Me
|
Others | Others |
SPI--112Me 是 SPI-112 的前药,在无细胞试验中,它优先抑制 Shp2 的 PTPase 活性超过 Shp1 和 PTP1B 20 倍。 | |||
T6911 |
NSC-87877 disodium
NSC87877 |
Apoptosis; Phosphatase | Apoptosis; Metabolism |
NSC-87877 disodium (NSC87877) 是一种有效的Shp2和Shp1蛋白质酪氨酸磷酸酶抑制剂,IC50值分别为0.318 μM 和0.355 μM。NSC-87877还抑制双特异性磷酸酶26。 | |||
T16878 |
SHP836
|
Others | Others |
SHP836 is an inhibitor of SHP2 allosteric (IC50: 12 μM for the full-length SHP2). | |||
T16877 |
SHP394
|
Others | Others |
SHP394 is an orally efficacious inhibitor of protein tyrosine phosphatase SHP2 (IC50: 23 nM). | |||
T39726 |
SHP389
SHP389 |
Others | Others |
SHP389 is an allosteric SHP2 inhibitor, with an IC 50 of 36 nM for both SHP2 and p-ERK. | |||
T39167 |
GS-493
|
Others | Others |
GS-493, a highly specific protein tyrosine phosphatase SHP2 (PTPN11) inhibitor, exhibits remarkable potency with an IC50 of 71 nM. It displays 29- and 45-fold greater affinity towards SHP2 compared to its related counterparts, SHP1 and PTP1B, respectively. In addition, GS-493 impedes both cellular motility and growth of cancer cells, portraying promising antitumor effects. | |||
T25953 |
PHPS1 Sodium
PHPS1 Na,PHPS1 Sodium salt |
Others | Others |
PHPS1 sodium 是 Shp2的选择性抑制剂,对 Shp2,Shp2-R362K,Shp1,PTP1B 和 PTP1B-Q 的Ki 值分别为 0.73,5.8,10.7,5.8 和 0.47 μM。 | |||
T70919 |
NAT6-297775
|
Others | Others |
NAT6-297775 is a SHP2 inhibitor with IC50 =2.47uM. | |||
T73477 |
SHP844
|
Others | Others |
SHP844为一SHP2抑制剂,IC50值为18.9 µM。SHP2为蛋白酪氨酸磷酸酶(PTP),调控酪氨酸磷酸化水平,影响细胞增殖、分化及存活。 | |||
T62798 |
GDC-1971
|
Others | Others |
GDC-1971 (compound 199) 是一种 SHP2 的抑制剂。 | |||
T69835 |
Plasiatine
|
Others | Others |
Plasiatine is a novel potent activator of the nonreceptor protein tyrosine phosphatase shp2 | |||
T69125 |
NSC-13030
|
Others | Others |
NSC-13030 is a Potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines | |||
T27591 |
II-B08
II-B 08,FAP1 Inhibitor,II-B-08,LMWPTP Inhibitor,Lyp Inhibitor III,CD45 Inhibitor V |
Others | Others |
II-B08 is a cell-permeable SHP2 inhibitor (IC50 = 5.5 µM). II-B08 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation. | |||
T62657 |
SHP504
|
Others | Others |
SHP504 是一种 SHP2 磷酸酶的抑制剂,能够作用于 SHP21–525 (IC50: 21 μM)。 | |||
T39999 |
IACS-15414
|
Others | Others |
IACS-15414 is a potent SHP2 inhibitor that is effective when administered orally, demonstrating an IC50 value of 122 nM. | |||
T79311 |
CNBCA
|
Others | Others |
CNBCA是一种有效的SHP2酶抑制剂,具有选择性和竞争性,IC50值为0.87 μM。该化合物可结合SHP2全长蛋白并抑制其酶活性,进而阻止Akt和ERK1/2的磷酸化,以及抑制BT474和MDA-MB468乳腺癌细胞的生长。CNBCA主要用于乳腺癌的研究。 | |||
T39221 |
RMC-3943
|
Others | Others |
RMC-3943 is a highly potent allosteric inhibitor of full-length SHP2, as demonstrated by its remarkable activity in a biochemical assay, with an IC50 value of 2.19 nM. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T79985 |
Cryptosporioptide A
|
Phosphatase | Metabolism |
Cryptosporioptide A (Compound 3)是一种从昆虫寄生真菌Cordyceps gracilioides中分离出的色素蛋白酪氨酸磷酸酶抑制剂,针对PTP1B、SHP2、CDC25B、LAR和SHP1等酶展示了抑制作用,其IC50值分别为7.3、5.7、7.6、>50、4.9 μg/mL。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-03125 |
SHP-2 Protein, Mouse, Recombinant (His)
SAP-2,Syp,PTP1D,SH-PTP2,SH-PTP3,SHP |
Mouse | HEK293 Cells |
SHP2, also known as PTPN11, belongs to the protein-tyrosine phosphatase(PTP) family, non-receptor class 2 subfamily. PTPs catalyze the removal of phosphate groups from tyrosine residues by the hydrolysis of phosphoric acid monoesters. They dephosphorylate EGFR, JAK2 and TYK2 kinases, promoting oncogenic transformation. SHP2 is widely expressed, with highest levels in heart, brain, and skeletal muscle. SHP2 acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participat... | |||
TMPJ-00537 |
Siglec-3/CD33 Protein, Human, Recombinant (hFc & His)
Myeloid Cell Surface Antigen CD33,CD33,Siglec-3,SIGLEC3,gp67... |
Human | HEK293 Cells |
CD33 is a type I Lectin belonging to the Ig superfamily. CD33 contains an N terminal Ig like V type domain, which mediates sialic acid binding, followed by one Ig like C2 type domain, a transmembrane region and a cytoplasmic tail containing two conserved immunoreceptor tyrosine based inhibition motifs (ITIMs). Eleven human Siglecs have been characterized. Siglecs 5 to 11 share a high degree of sequence similarity with CD33/Siglec3 both in their extracellular and intracellular regions. They are c... |